Target intelligence / Profile preview

Fat atypical cadherin 4 (FAT4)

Target
FAT4
Molecular classification
Cadherin superfamily, Protocadherin, Single transmembrane protein, Cell adhesion molecule, Atypical cadherin, Receptor (single-pass transmembrane)
01

Overview

Fat atypical cadherin 4 (FAT4) is a member of the cadherin superfamily and functions as a single-pass transmembrane cell adhesion molecule distinguished by a large extracellular domain containing 34 cadherin repeats, multiple laminin G-like and EGF-like motifs, and an intracellular domain involved in diverse signaling cascades[1][2][3]. FAT4 plays critical roles in planar cell polarity (PCP), tissue growth control via the Hippo signaling pathway, and regulation of non-canonical Wnt signaling, impacting tissue homeostasis and morphogenesis[1][2]. It forms high-affinity heterophilic complexes with Dachsous1 (Dchs1), and its function and structure are conserved across vertebrate evolution, acting as a tumor suppressor and emerging disease biomarker implicated in cancer and developmental disorders[1][2][3].\n\n**Notes:**\n- No clinically approved drugs are currently known to directly target FAT4; the field is still emerging regarding its therapeutic modulation.\n- FAT4 is considered a tumor suppressor: loss of function or mutational inactivation is frequently observed in cancers rather than being a classical druggable target today[1].\n- Its role in Hippo, PCP, and Wnt pathways makes it a key node in cell fate and proliferation regulation.

Other names
Protocadherin Fat 4FAT4CDHF14FATJNbla00548hFat4FAT-JCDHR11Cadherin family member 14FAT tumor suppressor homolog 4Fat-like cadherin protein FAT-Jcadherin-related family member 11HKLLS2NBLA00548VMLDS2putative protein product of Nbla00548
02

Biological functions

Cell adhesionRegulation of planar cell polarity (PCP)Regulation of Hippo signaling pathwayRegulation of Wnt signaling pathway (non-canonical)Control of cell growth and proliferationMaintenance of tissue homeostasisSignal transduction
03

Disease associations

Cancer (tumor suppressor role, frequently mutated in several cancer types)Developmental disorders (including defects in morphogenesis and neural development)Kidney diseaseCardiovascular disease
04

Safety considerations

Mutation or loss of FAT4 associated with increased cancer riskMutations in FAT4 may underlie certain developmental or kidney defects, highlighting challenges for therapeutic targeting
05

Biomarkers

FAT4 mutations as potential cancer biomarkersFAT4 expression as an emerging disease biomarker

Beyond the preview

Go deeper on Fat atypical cadherin 4 (FAT4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fat atypical cadherin 4 (FAT4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call